Several works have demonstrated that status epilepticus (SE) induced-neurodegeneration appears to involve an overactivation of N-methyl-D-aspartate receptors and treatment with high-affinity NMDAR antagonists is neuroprotective against this brain damage. However, these compounds display undesirable side effects for patients since they block physiological NMDA receptor dependent-activity. In this context, memantine (MN), a well tolerable low-affinity NMDAR channel blocker, will be a promising alternative, since it does not compromise the physiological role of NMDA receptors on synaptic transmission. The aim of the present study was to investigate if MN could attenuate seizure severity and neuronal cell death caused by SE induced early in life. Wistar rats (15 days old; n = 6-8 per group) received memantine (20 mg/kg i.p.) in six different treatments: 6 and 3 h before SE onset; concomitant with pilocarpine; 15min and 1h after SE onset; and four consecutive administrations (15 min, 6 h, 12 h, and 18 h) after pilocarpine injection. Neurodegeneration was quantified by fluoro-jade C staining. Treatment with memantine increase latency to SE onset only in groups treated 3 h before or concomitant with pilocarpine. In CA1 hippocampal subfield, memantine significantly reduced neurodegeneration at the following times: 3 h prior SE-onset, concomitant with pilocarpine, and 15 min after pilocarpine injection. For amygdala and thalamus, all post-SE onset treatments were able to decrease neurodegeneration. In conclusion, the present study showed that MN was neuroprotective against SE-induced neuronal death and this neuroprotection appears to be time-and region-dependent.
Introduction
Status epilepticus (SE) is "a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures" (Trinka et al., 2015) . It is most prevalent in children than adults and its annual incidence is 10 to 73 episodes/ 100,000 children, being more incident in children younger than two years of age (135/100,000 to 156/100,000 children) (Fencl et al., 2000; Majores et al., 2007; Raspall-Chaure et al., 2006) .
One of most remarkable SE-induced consequence early in life is a massive neuronal cell death observed in specific brain areas, such as temporal cortex, hippocampus, amygdala and thalamus, which may lead to a long-term alterations in neural network development and thus functional and cognitive deficits at adulthood (de Oliveira et al., 2008; Kubova et al., 2002; Sankar et al., 1998) . Although clinically used antiepileptic drugs, such as midazolam, diazepam, fosphenytoin, valproic acid, levetiracetam, and phenobarbital, have been recommended to stop convulsive SE (Glauser et al., 2016) , they have mostly failed to halt SE-induced neuronal degeneration (Abdalla et al., 2014; Ahmed et al., 2011; Kalemenev et al., 2016; Trinka et al., 2015) . SE-induced neuronal degeneration appears to involve an overactivation of N-methyl-D-aspartate receptors (NMDARs) (Holopainen, 2008) and treatment with high-affinity NMDAR antagonists, such as TCP, ketamine and MK-801, has been showed to be effective for preventing SE-induced neuronal death (Brandt et al., 2003; Lerner-Natoli et al., 1991; Stafstrom et al., 1997) . However, preventive protection of NMDAR antagonists seems to have a short "therapeutic time window", since this drugs were efficacious only when they were administered prior or up to 15 min after SE onset (Fujikawa, 1995; Fujikawa et al., 1994; Loss et al., 2012) . Furthermore, clinical use of high-affinity NMDAR antagonists is not recommended. High-affinity NMDAR antagonists cut off normal glutamatergic neurotransmission (Lipton, 2004) , causing thus severe and undesirable side effects for patients (Danysz and Parsons, 2002; Muir and Lees, 1995) .
In this context, memantine (MN) has been proposed as an effective NMDAR channel blocker (Chen and Lipton, 2006) . The pharmacodynamics of MN involves NMDAR fast blocking/unblocking kinetics and strong voltage-dependency. These characteristics culminate in a partial blockage of NMDAR, which does not compromise the physiological and neurochemical role of these receptors on synaptic neurotransmission (Johnson and Kotermanski, 2006; Parsons et al., 2007; Rammes et al., 2008) . Moreover, MN appears to be more tolerable for patients than classical highaffinity NMDAR antagonists (Chen and Lipton, 2006; Parsons et al., 1999; Parsons et al., 2007) . Recently, memantine was approved by the Food and Drug Administration to treat moderate-to-severe Alzheimer's disease (Parsons et al., 2007) .
Taking into account that NMDAR overactivation may be implicated in SE-induced neurodegeneration and memantine is a well tolerable partial NMDAR channel blocker, the aim of the present study was to investigate if MN could attenuate seizure severity and neuronal cell death induced by SE early in life.
Material and methods

Drugs
Pilocarpine hydrochloride and memantine were purchased from Sigma-Aldrich (USA). Fluoro-Jade C was purchased from Chemicon, Inc. (USA). Other chemicals were purchased from Nuclear (Brazil).
Animals
One hundred and thirtythree young Wistar rats were obtained from local breeding. The litters were culled to 7 pups. Each litter contained animals from all experimental groups and was composed of 1:1 male/female ratio approximately. Animals were housed under controlled environment: light/dark photoperiod cycle of 12/12 h (lights on at 7:00 a.m.) and room temperature of 21 AE 2 C. N was 6-8 animals/group. All procedures were approved by the Research Ethics Committee from Universidade Federal do Rio Grande do Sul (protocol number #25772).
Induction of status epilepticus and treatment interventions
Rat pups (15 days old) were injected (10 ml/kg) with LiCl (3 mEq/kg; i.p.) 15 h prior to pilocarpine (60 mg/kg; i.p.; SE group) or saline (0.9% NaCl; i.p.; non-SE group) administrations. According to our previous works (de Oliveira et al., 2011; Loss et al., 2012) , this pilocarpine dose causes SE in all animals without induces high mortality rate. Memantine (MN) (20 mg/kg; i.p.) (Chen et al., 1998; Stieg et al., 1999) or saline (0,9%) were administrated in both SEand non-SE groups in six different therapeutic regimens: (I) 6 and (II) 3h prior to pilocarpine injection; (III) concomitant with pilocarpine injection; (IV) 15 min and (V) 1h after pilocarpine injection; and (VI) four consecutive administrations of MN (15 min, 6 h, 12 h, and 18 h) after pilocarpine injection ( Supplementary  Fig. S1 ). Treated rats were kept in individual plastic cages during 3 h for seizure observation. Behavioral manifestations of seizure were recorded and scored accordingly to Racine scale (Racine, 1972) . After this period, animals returned to home cages and were observed for more 1 h for seizure recovery. Animals spontaneously recovered from SE without anticonvulsant administration. Twenty-four hours after SE induction, animals were used to determine neuronal degeneration.
Fluoro-jade C staining
For evaluating neuronal degeneration, Fluoro-jade C staining (FJC) was conducted as described by Schmued et al. (2005) . Briefly, 24 h after SE induction rats were deeply anesthetized i.p. with ketamine (90 mg/kg) and xylazine (12 mg/kg) and sequentially perfused through the heart with 200 mL of ice-cold 0.1 M sodium phosphate buffer, pH 7.4, followed by 100 mL of ice-cold fixative solution (4% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4). Brains were removed and immersed overnight in fixative solution followed by 30% sucrose until brains sank to the bottom of the chamber. Coronal slices (30 mm) were obtained using a Leica VT 1000S vibroslicer, mounted on to gelatin-coated slides and dried at room temperature overnight. Slides were immersed in alcohol solution consisting of 1% sodium hydroxide in 80% ethanol for 5 min. Then, slides were rinsed for 2 min in 70% ethanol, 2 min in distilled water, and then incubated in 0.06% potassium permanganate solution during 10 min. After rinsing with distilled water for 2 min, slides were transferred for 10 min to a 0.0001% FJC solution dissolved in 0.1% acetic acid, washed three times for 1 min with distilled water, dried at room temperature overnight, dehydrated in xylene, and cover slipped. Sections were analysed using a Nikon Eclipse E600 epifluorescence microscope.
Total number of FJC-positive cells per animal corresponds to an average of 3 consecutive coronal brain sections from plates 31-33 of Paxinos and Watson's Atlas (1998). Cells were counted at 200x magnification by using the software NIS-Elements Version 3.10 (Nikon Instruments Inc., USA). Only cells exhibiting bright green fluorescence and neuronal profile were counted (Wang et al., 2008) . Brain regions analysed were thalamus, amygdala and hippocampus, which were chosen accordingly to previous studies (de Oliveira et al., 2008; Kubova et al., 2002) .
Statistical analysis
All data were first tested for normality by D'Agostino-Pearson omnibus normality test. Two-way ANOVA followed by Bonferroni post hoc test was used to analyse latency to SE onset and results were expressed as mean AE S.E.M. Mann-Whitney U-test was used to analyse FJC data and results were expressed as median (interquartile range). P < 0.05 was considered significant.
Results
Systemic administration of LiCl-pilocarpine produced defecation, salivation, body tremor, and scratching within 5 to 10 min. This behavioral pattern progressed within 20 to 45 min to increased levels of motor activity and culminated in SE in all animals. SE was characterized by sustained orofacial automatisms, salivation, chewing, forelimb clonus, loss of the righting reflex and falling, and lasting up to 3-4 h. Treatment with MN increased the latency to generalized motor convulsions (stage 5 of Racine scale) only when it was administered 3h before or concomitant with pilocarpine (p = 0.0385 and p = 0.0055, respectively; Fig. 1 ). For the other Racine stages, MN had no effect. Additionally, MN treatment was not able to decrease mortality rates.
FJC-positive cells exhibited a bright green color in the soma and in the fine neuronal processes ( Figs. 2 and 3 ; insets showing higher magnification view). Twenty-four hours after SE onset, animals treated with LiCl-pilocarpine + saline presented an expressive neuronal degeneration in CA1 and DG hippocampal subfields, as well as in posteroventral medial nucleus (MePV) of amygdala and ventral posteromedial nucleus (VPM) of thalamus (Figs. 2 and 3) . Pre-and post-therapeutic regimens with MN did not reduce the number of FJC-positive neurons in DG ( Fig. 2; Table 1 ). In contrast, the number of FJC-positive cells in CA1 subfield was significantly reduced when animals were treated with MN 3h before, concomitant or 15 min after pilocarpine administration (p = 0.008, p = 0.024 and p = 0.002, respectively) ( Fig. 2; Table 1 ). At 1h after pilocarpine or multiple injections regimen, MN did not reduce the number of FJC-positive cells in CA1 subfield.
In MePV nucleus of amygdala, MN administered 15 min or 1 h after pilocarpine reduced significantly the number of FJC-positive neurons (p = 0.001 and p = 0.004, respectively). Moreover, in this brain region a protective effect was also observed when MN was administered in a multiple injections regimen (p = 0.017) ( Fig. 3 ; Table 1 ).
For VPM nucleus of thalamus, MN was protective in all treatment regimens ( Fig. 3; Table 1 ).
None FJC-positive neurons were observed in non-SE animals treated with saline or MN (data not shown).
Discussion
Massive neuronal cell death is one of the most remarkable consequences of SE for the developing brain. It has been considered a critical signal to induce abnormal axonal sprouting and synapticcircuit reorganization, which have been pointed as a structural and functional basis for behavioral and cognitive dysfunctions observed in adult epileptic patients. Neuronal cell death induced by SE appears to involve an overactivation of NMDAR (Holopainen, 2008) and treatment with NMDAR antagonists, such as MK-801 and ketamine, was shown to prevent SE-induced neurodegeneration in several experimental models (Brandt et al., 2003; LernerNatoli et al., 1991; Stafstrom et al., 1997) . However, clinical use of high-affinity NMDAR antagonists is not recommended, since they can block physiological glutamatergic neurotransmission causing severe and undesirable side effects for patients (Danysz and Parsons, 2002; Lipton, 2004; Muir and Lees, 1995) .
In this context, development and testing drugs that potentially prevent SE-induced neurodegeneration without, however, affecting normal neurotransmission can be crucial for clinical management of pediatric SE. In present work, we showed that MN, an effective NMDAR channel blocker with fast blocking/unblocking kinetics, was able to reduce SE-induced neuronal degeneration in the developing brain. MN neuroprotection was time-and regiondependent and may be attributed to its capacity of blocking GluN2A-and GluN2B-containing NMDAR, which are highly expressed in immature brain (Monyer et al., 1994; Paoletti et al., 2013) .
MN neuroprotection observed in CA1 subfield may represent the ability of MN bind to channels formed by these both NMDAR subunits, since Bresink et al. (1996) and Parsons et al. (1999) have demonstrated that MN was equipotent for blocking glutamateinduced currents mediated by GluN2A-and GluN2B-containing NMDAR in hippocampal slices. However, we observed a complete lack of neuroprotection in DG. This can be attributed to a later NMDA receptor maturation in this region. According to Bekenstein and Lothman (1991) , hippocampal NMDA receptor dependent-LTP reaches the adult values about two weeks after birth in CA1, while for DG this value is reached only about 3 weeks after birth. Since our animals are two-weeks old, NMDAR functional immaturity can confer a reduced sensibility of DG to MN, which would preclude its neuroprotective action (McDonald et al., 1990) .
Post-SE onset treatments in amygdala and thalamus showed a highest neuroprotective effect of MN. Comparatively with the hippocampus, there is a massive expression of GluN2B subunits in amygdala and thalamus during the first and second weeks of life in rats (Lopez de Armentia and Sah, 2003) . Since MN present high affinity for GluN2B subunits, neuroprotective effects observed in these regions probably can be attributed to this increased expression of GluN2B subunits (Grimwood et al., 1996) . Surprisingly, MN also showed a prominent neuroprotection in VPM. This neuroprotection can be attributed to distinct compositions of NMDAR subunits in thalamus. For instance, Paoletti et al. (2013) have shown that the expression of NMDAR subunits in thalamus during brain development comprises GluN1/GluN2A, GluN1/GluN2B and GluN1/GluN2D and literature have reported that MN is particularly able to interact with all of these functional isoforms (Parsons et al., 2007) .
Excitotoxicity caused by excessive neuronal activity has been proposed as molecular mechanism implicated in SE-induced neuronal cell death (Choi, 1992) . This pathological process is mediated mainly by an overactivation of NMDA receptors, which can lead to an excessive calcium entry into neuronal cytosol and a subsequent activation of proteases, phospholipases and endonucleases (Szado et al., 2008; Wang et al., 1999) . Neuronal cell death can also be induced by an elevation of [Ca +2 ]i, which may be mediated by Ca +2 release from IP3-and ryanodine-sensitive calcium stores (Deshpande et al., 2016; Deshpande et al., 2014) . Moreover, SE also can disrupt glial glutamate uptake and reduce Na + /K + ATPase activity (de Oliveira et al., 2011) , which may lead to an elevation of glutamate levels on synaptic cleft and, subsequently, an exacerbation of excitotoxic neuronal injury (Rothman and Olney, 1995; Yan et al., 2013) . Since excitotoxicity has been proposed to be one of the molecular mechanisms involved in SEinduced neuronal cell death, NMDAR channel-blockers that do not impair physiological neurotransmission could be considered as an adjuvant therapy for SE-induced neurodegeneration. This notion can be reinforced by the fact that clinically used antiepileptic drugs have a time-dependent loss of effectiveness against SE-induced brain injury, i.e. they are protective only when they are administered early or immediately after SE onset (George and Kulkarni, 1996; Kim et al., 2007; Mazarati et al., 1998; Morrisett et al., 1987; Sofia et al., 1993) . Few AEDs exhibit significant neuroprotection against SE-induced neuronal damage when they are administered after SE onset (Abdalla et al., 2014; Kalemenev et al., 2016) .
In our study, we showed that MN was able to reduce neuronal damage in thalamus and amygdala even when it was administered at a single injection after SE onset. Neuroprotection was also observed when it was administered at a post-SE multiple injection therapeutic regimen. These findings have a potential clinical value, since classical AEDs failed into protect the brain from SE-induced neuronal damage (Temkin, 2009 ). Neuroprotection following brain insults does not seem to provide a promising strategy to prevent epilepsy, but may reduce or prevent other consequences of brain insults, such as cognitive deficits or psychopathology in adulthood (Loscher and Brandt, 2010) .
Several NMDAR antagonists, including MN, exert anticonvulsant activity in some animal models. Dhir and Chopra (2015) demonstrated that MN pre-treatment delayed the onset of different phases of NMDA-induced convulsions in neonatal rats at dose-dependent manner. Moreover, MN also suppressed generalized tonic-clonic PTZ-induced seizures in immature rats (Mares and Mikulecka, 2009) . However, in our study MN does not seem to be a promising strategy to stop LiCl-pilocarpine-induced seizures, although it increased latency to generalized motor convulsions. This distinct anticonvulsant profile of MN can be associated with peculiarities of each seizure-induced animal model, such as type of induced-seizure and chemoconvulsant target site (Kupferberg, 2001) . Despite this controversial anticonvulsant activity, as well as some intolerable side effects (Creeley Loscher and Honack, 1990) , MN may be a very promising therapeutic strategy for ameliorates cognitive impairments associated with early-life SE. Post-treatment with MN prevented impaired exploratory behavior and spatial memory deficits, and a decline of spatial memory-extinction in pilocarpineinduced SE (Kalemenev et al., 2016) .
Our data suggest that cellular mechanisms underlying seizure maintenance and neurodegeneration at LiCl-pilocarpine-induced SE involve distinct signaling pathways. To analyse the mechanisms responsible for sustained SE, it is necessary to know exactly the brain regions involved and mechanisms of seizure propagation in pilocarpine model, especially because we demonstrated that MN exerts region-dependent effects. For example, substantia nigra is a crucial site of anticonvulsant activity, while forebrain and hindbrain areas had no significant contribution (Iadarola and Gale, 1982; Lado and Moshe, 2008) and this could limit the full effect of MN. Differences between pharmacodynamics of MN and others NMDAR antagonists have been proposed to more potent inhibition of extrasynaptic than synaptic NMDAR by MN (Parsons et al., 2007; Xia et al., 2010; Zhou et al., 2013) . MN binding depends upon intracellular calcium concentration and thus on the intensity of NMDAR activation, as well as on duration of glutamate exposure in an NMDAR subtype-dependent manner, and compared to others NMDAR antagonists, differentially alter NMDAR desensitization (Glasgow et al., 2017) . Thus, kinetic proprieties also could contribute to less efficiency to MN for stop seizure. Furthermore, MN (6 -10 mM) did not attenuate LTP in hippocampal slices and substantially spared the NMDA component of excitatory postsynaptic currents, while MK-801 at same concentrations or APV (50 mM) completely blocked these events (Chen et al., 1998) . Thus, we hypothesized that MN promotes fewer anticonvulsive effects through NMDAR-mediated overactivity, displaying a less pronounced effect than other NMDAR antagonists, due to the more rapid unblocking rate of MN.
In summary, our results showed that treatment with MN was able to protect the brain against SE-induced neuronal damage in a time-and spatial-dependent manner. Since MN is an FDAapproved drug, our experimental data may point to the putative use of this drug in futures prospective clinical trials involving neuroprotection against SE-induced brain damage.
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